Drug Shortage Report for EMGALITY

Last updated on 2023-01-17 History
Report ID 173230
Drug Identification Number 02505134
Brand name EMGALITY
Common or Proper name galcanezumab injection
Company Name ELI LILLY CANADA INC
Market Status MARKETED
Active Ingredient(s) GALCANEZUMAB
Strength(s) 100MG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS
Packaging size Carton package containing three 100 mg/mL prefilled syringes
ATC code N02CD
ATC description
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-10-27
Estimated end date 2023-01-16
Actual end date 2023-01-16
Shortage status Resolved
Updated date 2023-01-17
Company comments For any questions or concerns, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays).
Health Canada comments
Tier 3 Status No
Contact Address EXCHANGE TOWER, 130 KING STREET WEST
TORONTO, ONTARIO
CANADA M5X 1B1
Company contact information Lilly Canada’s Customer Response Centre 1-888-545-5972.

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v1 2022-11-01 English Compare
v2 2022-11-01 French Compare
v3 2023-01-16 English Compare
v4 2023-01-16 French Compare
v5 2023-01-17 English Compare

Showing 1 to 5 of 5